Biological Activity
MG-115(MG 115) is an inhibitor of NFκB in the cytoplasm by acting on IKK or the proteasome.
In Vitro
MG-115 (0.1-10 μM; 24 h) dose-dependently decreases the viability of HepG2 cells[3]. MG-115 (0.1-10 μM; 24 h) amplifies the reporter gene expression mediated by CWK18 DNA condensates[3]. Cell Viability Assay[3] Cell Line: HepG2 cells Concentration: 0.1, 1, 2, 5, 10 μM Incubation Time: 24 hours Result: Dose-dependently decreased cell viability. Inhibited the proteasomal activity, with an IC50 of 2 μM.
In Vivo
No in vivo data are provided in the current product source. Contact us for further information.
Target
Ki: 21 nM (20S proteasome); 35 nM (26 Sproteasome)[1]
References & source
[1]. Rock KL, et, al. Inhibitors of the proteasome block the degradation of most cell proteins and the generation of peptides presented on MHC class I molecules. Cell. 1994 Sep 9;78(5):761-71.
[2]. Lopes UG, et, al. p53-dependent induction of apoptosis by proteasome inhibitors. J Biol Chem. 1997 May 16;272(20):12893-6.
[3]. Kim J, et, al. The proteasome metabolizes peptide-mediated nonviral gene delivery systems. Gene Ther. 2005 Nov;12(21):1581-90.
Published experimental findings depend on the model and assay conditions. They do not guarantee equivalent performance in every application. For laboratory research use only.
